Trial in progress: A phase II, multicenter, open-label study of PolyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301).

被引：0
|
作者：
Hubbard, Joleen M.
Ahn, Daniel H.
Jones, Jeremy Clifton
Wittenberger, Kathleen
Molnar, Levente
Lorincz, Orsolya
Somogyi, Eszter
Csiszovszki, Zsolt
Youssoufian, Hagop
Toke, Eniko Rita
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Mayo Clin Arizona, Phoenix, AZ USA
[3] Mayo Clin, Jacksonville, FL USA
[4] Treos Bio, Veszprem, Hungary
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS283
引用
收藏
页码：TPS283 / TPS283
页数：1
相关论文
共 50 条
  • [1] A phase II, multicenter, open-label study of polyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301).
    Hubbard, Joleen M.
    Ahn, Daniel H.
    Jones, Jeremy Clifton
    Zhu, Mojun
    Wittenberger, Kathleen
    Csiszovszki, Zsolt
    Somogyi, Eszter
    Lorincz, Orsolya
    Molnar, Levente
    Toth, Jozsef
    Youssoufian, Hagop
    Toke, Eniko Rita
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] A phase II, multicenter, open-label study of PolyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301): Initial results
    Hubbard, J.
    Ahn, D.
    Jones, J. C.
    Jin, Z.
    Zhu, M.
    Xie, H.
    Novo, E.
    Graham, R.
    Wittenberger, K.
    Kremlitzka, M.
    Csiszovszki, Z.
    Somogyi, E.
    Lorincz, O.
    Molnar, L.
    Toth, J.
    Youssoufian, H.
    Toke, E. R.
    ANNALS OF ONCOLOGY, 2023, 34 : S452 - S452
  • [3] PolyPEPI1018 vaccine in combination with TAS-102 in participants with late-stage microsatellite-stable metastatic colorectal cancer (MSS mCRC): A phase Ib study to evaluate safety, tolerability, immunogenicity and efficacy (OBERTO-201)
    Hubbard, Joleen M.
    Zemla, Tyler J.
    Graham, Rondell P.
    Jin, Zhaohui
    Zhu, Mojun
    Mitchell, Jessica L.
    Novo, Elise
    Vegh, Eva
    Lorincz, Orsolya
    Csiszovszki, Zsolt
    Kremlitzka, Mariann
    Somogyi, Eszter
    Molnar, Levente
    Toth, Jozsef
    Toke, Eniko Rita
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Phase Ib open-label study to evaluate safety, tolerability, immunogenicity, and efficacy of multiple subcutaneous injections of PolyPEPI1018 vaccine as an add-on immunotherapy to TAS-102 in participants with late-stage microsatellite-stable metastatic colorectal cancer (MSS mCRC; OBERTO-201).
    Hubbard, Joleen M.
    Zemla, Tyler J.
    Graham, Rondell P.
    Jin, Zhaohui
    Zhu, Mojun
    Mitchell, Jessica L.
    Novo, Elise
    Vegh, Eva
    Lorincz, Orsolya
    Kremlitzka, Mariann
    Somogyi, Eszter
    Molnar, Levente
    Toth, Jozsef
    Toke, Eniko Rita
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 147 - 147
  • [5] Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study
    Hubbard, Joleen M.
    Toke, Eniko R.
    Moretto, Roberto
    Graham, Rondell P.
    Youssoufian, Hagop
    Lorincz, Orsolya
    Molnar, Levente
    Csiszovszki, Zsolt
    Mitchell, Jessica L.
    Wessling, Jaclynn
    Toth, Jozsef
    Cremolini, Chiara
    CLINICAL CANCER RESEARCH, 2022, 28 (13) : 2818 - 2829
  • [6] PolyPEPI1018 off-the shelf vaccine as add-on to maintenance therapy achieved durable treatment responses in patients with microsatellite-stable metastatic colorectal cancer patients (MSS mCRC)
    Hubbard, Joleen
    Cremolini, Chiara
    Graham, Rondell
    Moretto, Roberto
    Mitchell, Jessica
    Wessling, Jaclynn
    Toke, Eniko
    Csiszovszki, Zsolt
    Lorincz, Orsolya
    Molnar, Levente
    Somogyi, Eszter
    Megyesi, Monika
    Pantya, Kata
    Toth, Jozsef
    Pales, Peter
    Miklos, Istvan
    Falcone, Alfredo
    Hubbard, Joleen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [7] Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) plus Imprime PGG (Imprime) plus bevacizumab (bev) vs regorafenib (rego) in MORPHEUS: Microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
    Fakih, Marwan
    Cleary, James M.
    Hong, Yong Sang
    Kim, Tae-You
    Safyan, Rachael A.
    Allen, Simon
    Bailey, Lorna
    Cha, Edward
    Lenain, Christelle
    Lu, Danny
    Schulze, Jochen
    Shemesh, Colby S.
    Zimmermann, Stefan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Efficacy and safety of cobimetinib (cobi) and atezolizumab (atezo) in an expanded phase 1b study of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC)
    Desai, J.
    Hong, Y. S.
    Kim, J. E.
    Kim, T. W.
    Han, S. W.
    Bang, Y-J.
    Chee, C. E.
    Heong, V. Y. M.
    Mcree, A.
    Chow, L. Q.
    Kwak, E. L.
    Infante, J. R.
    Wallin, J.
    Das Thakur, M.
    Mwawasi, G.
    Foster, P.
    Cha, E.
    Bendell, J. C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Interim analysis of the AVETUXIRI Trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC)-A proof of concept, open-label, nonrandomized phase IIa study.
    Van den Eynde, Marc
    Huyghe, Nicolas
    De Cuyper, Astrid
    Sinapi, Isabelle
    Ferrier, Marie
    Gilet, Melanie
    Van Maanen, Aline
    Castella, Marie-Laure
    Galon, Jerome
    Carrasco, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [10] Results of a phase II study evaluating trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
    Patel, Manish R.
    Falchook, Gerald Steven
    Hamada, Kensuke
    Makris, Lukas
    Winkler, Robert E.
    Gordon, Gilad Shalag
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
12345